jdq443
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Feb 24, 2021 (NCT04699188)
Timeline
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1- Mol. weight
- 526.04 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5077861 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05999357 | Phase 2 | Nov 30, 2023 | Maastricht University, Novartis |
| NCT05714891 | Phase 2 | Sep 15, 2023 | Canadian Cancer Trials Group, McGill University, Novartis |
| NCT05445843 | Phase 2 | Dec 6, 2022 | Novartis |
| NCT05358249 | Phase 1/Phase 2 (Phase 2) | Oct 24, 2022 | Novartis |
| NCT05329623 | Phase 1 | May 3, 2022 | Novartis |
| NCT05132075 | Phase 3 | Mar 1, 2022 | Novartis |
| NCT04699188 | Phase 1/Phase 2 (Phase 2) | Feb 24, 2021 | Novartis |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 7 | 5 | 3 | 2021 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Maastricht University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1